| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| BUY | SELL | SELL | NEUTRAL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 5.29▼ | 5.26▲ | 5.25▲ | 5.39▼ | 4.85▲ |
| MA10 | 5.26▲ | 5.29▼ | 5.38▼ | 5.08▲ | 6.00▼ |
| MA20 | 5.42▼ | 5.35▼ | 5.31▼ | 4.84▲ | 6.78▼ |
| MA50 | 4.96▲ | 4.81▲ | 4.73▲ | 6.24▼ | 7.39▼ |
| MA100 | 4.66▲ | 4.89▲ | 5.42▼ | 6.98▼ | 7.51▼ |
| MA200 | 5.27▲ | 6.24▼ | 6.50▼ | 7.63▼ | 10.15▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.048▼ | -0.048▼ | -0.046▼ | 0.189▲ | -0.269▼ |
| RSI | 52.228▲ | 55.179▲ | 54.193▲ | 47.410▼ | 37.652▼ |
| STOCH | 39.777 | 24.865 | 18.148▼ | 91.975▲ | 20.199 |
| WILL %R | -75.000▼ | -75.000▼ | -75.000▼ | -23.649▲ | -66.327 |
| CCI | -36.949 | -33.875 | -57.299 | 64.023 | -71.757 |
|
Wednesday, April 30, 2025 04:51 AM
The market for obesity drugs presents one of the most lucrative targets for biopharmaceutical companies. Eli Lilly and Novo Nordisk are already raking in billions of dollars in sales with their weight ...
|
|
Wednesday, April 30, 2025 01:50 AM
Altimmune and Viking Therapeutics have promising obesity drugs and could be great acquisition targets for Pfizer. Pfizer should be able to easily fund an acquisition of either small drugmaker. The ...
|
|
Tuesday, April 29, 2025 08:32 AM
EPS estimates, maintains 2025 guidance, and targets $5.7 billion in cost savings through automation and R&D streamlining.
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 01/05/25 | 5.38 | 5.38 | 5.05 | 5.27 | 83,594 |
| 30/04/25 | 5.4041 | 5.69 | 5.38 | 5.61 | 368,092 |
| 29/04/25 | 5.60 | 5.60 | 5.54 | 5.54 | 65,571 |
| 28/04/25 | 5.20 | 5.425 | 5.20 | 5.35 | 38,789 |
| 25/04/25 | 5.00 | 5.20 | 4.92 | 5.20 | 38,453 |
| 24/04/25 | 4.80 | 5.15 | 4.80 | 5.15 | 54,000 |
| 23/04/25 | 4.99 | 5.08 | 4.835 | 4.85 | 46,938 |
| 22/04/25 | 4.57 | 4.7499 | 4.5638 | 4.72 | 25,547 |
| 21/04/25 | 4.51 | 4.58 | 4.3708 | 4.48 | 44,259 |
| 17/04/25 | 4.42 | 4.61 | 4.42 | 4.59 | 53,756 |
|
|
||||
|
|
||||
|
|